Edwards Lifesciences Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bernard J. Zovighian
- Full Time Employees
- 16,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- One Edwards Way Irvine CA United States of America 92614
- IPO Date
- Mar 27, 2000
- CIK
- 0001099800
- Website
- edwards.com
- Similar Companies
- Business
- Edwards Lifesciences Corporation is a medical technology company specializing in structural heart disease treatments, primarily manufacturing and marketing surgical heart valve repair and replacement devices, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and hemodynamic monitoring systems. Its core products include the SAPIEN transcatheter heart valve line used in aortic stenosis treatments, the PASCAL transcatheter repair system for mitral and tricuspid valves, the Evoque transcatheter tricuspid valve replacement, and a portfolio of surgical heart valves and accessories. The company also provides advanced tissue technologies under the RESILIA platform and pressure and hemodynamic monitoring devices for critical care applications. Edwards operates globally with manufacturing facilities and commercial operations in the United States, Costa Rica, Dominican Republic, Puerto Rico, Singapore, and Ireland. Founded in 1958, it is headquartered in Irvine, California. Recent major company developments include Edwards' strategic expansion via acquisitions, notably JenaValve Technology and Endotronix, which it acquired for approximately $1.6 billion in 2024 to enhance its structural heart disease portfolio with emerging treatments for aortic regurgitation and heart failure monitoring. In mid-2024, Edwards completed the sale of its Critical Care product group to Becton, Dickinson and Company (BD) for $4.2 billion, reflecting a strategic focus shift to core structural heart innovations. The company continues to advance its product pipeline with upcoming FDA approvals, including the SAPIEN M3 transcatheter mitral valve system projected for early 2026 and the next-generation PASCAL system slated for late 2026. Edwards is also preparing to launch the TRIFORMIS surgical valve for the tricuspid position in the U.S. in the second half of 2026 and expects significant clinical trial milestones in 2026. Its financial outlook remains strong, with projected sales growth of 8-10% for 2026 and ongoing development in structural heart therapies and expanded treatment indications.
Company News
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
EW DCF Analysis: Intrinsic Value $53 vs Price $86
Edwards Lifesciences Comments on TAVR National Coverage Decision
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
128,603 Shares in Edwards Lifesciences Corporation $EW Acquired by Beacon Pointe Advisors LLC
Is EW Overvalued? DCF Says Worth $53
Bank of Nova Scotia Takes Position in Edwards Lifesciences Corporation $EW
37,702 Shares in Edwards Lifesciences Corporation $EW Bought by EP Wealth Advisors LLC
B. Metzler seel. Sohn & Co. AG Buys Shares of 41,753 Edwards Lifesciences Corporation $EW
Allworth Financial LP Takes Position in Edwards Lifesciences Corporation $EW
Should You Hold Edwards Lifesciences Stock in Your Portfolio?
BlackRock Inc. Acquires New Stake in Edwards Lifesciences Corporation $EW
Baxter Bros Inc. Invests $3.54 Million in Edwards Lifesciences Corporation $EW
Bank Hapoalim BM Makes New $1.78 Million Investment in Edwards Lifesciences Corporation $EW
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
EW DCF Analysis: Intrinsic Value $53 vs Price $90
Edwards Lifesciences Corporation $EW Stock Holdings Lessened by Glenmede Trust Co. NA